Literature DB >> 17574972

Modulation of dopaminergic and glutamatergic brain function: PET studies on parkinsonian rats.

Daniela Pellegrino1, Francesca Cicchetti, Xukui Wang, Aijun Zhu, Mexiang Yu, Martine Saint-Pierre, Anna-Liisa Brownell.   

Abstract

UNLABELLED: Degeneration of dopaminergic neurons of the substantia nigra pars compacta is a cardinal feature of Parkinson's disease (PD). Although uncertain, the pathology has been suggested to derive from a malfunction of the complex interaction between dopaminergic and metabotropic glutamate receptors (mGluRs). To further address this issue, we investigated the imaging profile and expression of dopamine D(2) receptors and mGluRs in a classic parkinsonian rodent model induced by the toxin 6-hydroxydopamine.
METHODS: Adult male Sprague-Dawley rats (250-300 g) received a stereotaxic injection of 8 mug/2 muL of 6-hydroxydopamine (n = 6) or saline solution (n = 4) in the right medial forebrain bundle. Small-animal PET was performed on all rats 4 wk after the surgical procedure to assess dopamine transporter (DAT) status using (11)C-2beta-carbomethoxy-3beta-(4-fluorophenyl)-tropane (CFT), as well as dopamine D(2) receptor and mGluR(5) modulation using (11)C-raclopride and 2-(11)C-methyl-6-(2-phenylethynyl)-pyridine ((11)C-MPEP), respectively. Behavioral studies were also conducted 6 wk after lesioning by d-amphetamine challenge. Immunohistochemistry and Western blotting were carried out at 8 wk after lesioning to confirm dopamine fiber, neuronal loss, and level of striatal mGluR(5) expression.
RESULTS: PET images showed decreased (11)C-CFT binding on the lesioned side, including the structures of the striatum, hippocampus, and cortex, compared with the contralateral intact side. Interestingly, dopamine D(2) receptors and mGluR(5) upregulation were observed in the right striatum, hippocampus, and cortex, using (11)C-raclopride and (11)C-MPEP, respectively. A negative correlation was also found between the percentage change in mGluR(5) expression and DAT function. Finally, tyrosine hydroxylase immunoreactivity confirmed both dopamine fiber loss (t test, P < 0.01) and neuronal loss (t test, P < 0.01) on the lesioned side. These changes were accompanied by a strongly enhanced mGluR(5) expression in the right striatum of the lesioned side analyzed by Western plot.
CONCLUSION: These findings support the existence of compensatory mechanisms in nigrostriatal dopamine degeneration and provide new insights that help further dissect some of the pathways underlying neurodegeneration. In addition, these results reconfirm that PET is a valuable tool for multilevel receptor studies, significantly contributing to the understanding of pathogenic mechanisms and ultimately opening new avenues in the study of neuroprotective approaches toward PD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17574972     DOI: 10.2967/jnumed.106.037796

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  21 in total

1.  Enhanced binding of metabotropic glutamate receptor type 5 (mGluR5) PET tracers in the brain of parkinsonian primates.

Authors:  R Sanchez-Pernaute; J-Q Wang; D Kuruppu; L Cao; W Tueckmantel; A Kozikowski; O Isacson; A-L Brownell
Journal:  Neuroimage       Date:  2008-04-20       Impact factor: 6.556

2.  Microfluidic continuous-flow radiosynthesis of [18F]FPEB suitable for human PET imaging.

Authors:  Steven H Liang; Daniel L Yokell; Raul N Jackson; Peter A Rice; Ronald Callahan; Keith A Johnson; David Alagille; Gilles Tamagnan; Thomas Lee Collier; Neil Vasdev
Journal:  Medchemcomm       Date:  2014-04-01       Impact factor: 3.597

3.  PET imaging of metabotropic glutamate receptor subtype 5 (mGluR5).

Authors:  Dan Li; Hong Shan; Peter Conti; Zibo Li
Journal:  Am J Nucl Med Mol Imaging       Date:  2011-12-15

4.  PDZ Scaffold Protein CAL Couples with Metabotropic Glutamate Receptor 5 to Protect Against Cell Apoptosis and Is a Potential Target in the Treatment of Parkinson's Disease.

Authors:  Wen Yuan Luo; Su Qian Xing; Ping Zhu; Chen Guang Zhang; Hui Min Yang; Nicholas Van Halm-Lutterodt; Li Gu; Hong Zhang
Journal:  Neurotherapeutics       Date:  2019-07       Impact factor: 7.620

Review 5.  Development of allosteric modulators of GPCRs for treatment of CNS disorders.

Authors:  Hilary Highfield Nickols; P Jeffrey Conn
Journal:  Neurobiol Dis       Date:  2013-09-27       Impact factor: 5.996

6.  Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease.

Authors:  Yolanda D Black; Danqing Xiao; Daniela Pellegrino; Anil Kachroo; Anna-Liisa Brownell; Michael A Schwarzschild
Journal:  Neurosci Lett       Date:  2010-09-18       Impact factor: 3.046

Review 7.  How Relevant Are Imaging Findings in Animal Models of Movement Disorders to Human Disease?

Authors:  Darryl Bannon; Anne M Landau; Doris J Doudet
Journal:  Curr Neurol Neurosci Rep       Date:  2015-08       Impact factor: 5.081

8.  PKCδ knockout mice are protected from para-methoxymethamphetamine-induced mitochondrial stress and associated neurotoxicity in the striatum of mice.

Authors:  Eun-Joo Shin; Duy-Khanh Dang; Hai-Quyen Tran; Yunsung Nam; Ji Hoon Jeong; Young Hun Lee; Kyung Tae Park; Yong Sup Lee; Choon-Gon Jang; Jau-Shyong Hong; Toshitaka Nabeshima; Hyoung-Chun Kim
Journal:  Neurochem Int       Date:  2016-09-10       Impact factor: 3.921

9.  Selective hyposmia in Parkinson disease: association with hippocampal dopamine activity.

Authors:  Nicolaas I Bohnen; Satyanarayana Gedela; Priyantha Herath; Gregory M Constantine; Robert Y Moore
Journal:  Neurosci Lett       Date:  2008-09-30       Impact factor: 3.046

10.  PET imaging in rats to discern temporal onset differences between 6-hydroxydopamine and tau gene vector neurodegeneration models.

Authors:  Ronald L Klein; Robert D Dayton; Tracee L Terry; Chris Vascoe; John J Sunderland; Kerrie H Tainter
Journal:  Brain Res       Date:  2009-02-10       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.